Kyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley

Morgan Stanley analyst Michael Ulz raised the firm’s price target on Kyverna Therapeutics (KYTX) to $33 from $25 and keeps an Overweight rating on the shares. Top line data from the Phase 2 registrational study of mivocabtagene autoleucel in stiff person syndrome confirm robust, consistent activity and favorable tolerability, says the analyst, who views the results as “very positive.”